Search results
Hims & Hers Is Now Selling Semaglutide: Here's What You Should Know
Verywell Health via Yahoo Finance· 7 hours agoCompounded drugs are not approved by the Food and Drug Administration (FDA), and do not require...
FDA greenlights SAB Biotherapeutics' diabetes drug trial By Investing.com
Investing.com· 16 hours agoThe U.S. Food and Drug Administration (FDA) has cleared SAB Biotherapeutics' investigational new...
FDA issues recall notice for Philips after another respiratory device fails
Medical Device Network via Yahoo Finance· 7 days agoThe FDA has issued the notice for the company’s Trilogy EVO Continuous Ventilators, warning that...
What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
Benzinga· 12 hours agoTuesday, the FDA's staff reviewers raised concerns regarding Guardant Health Inc's GH experimental...
FDA lifts hold on Larimar's Friedreich's Ataxia drug study By Investing.com
Investing.com· 1 day agoLarimar Therapeutics, Inc. (NASDAQ:LRMR), a biotechnology firm engaged in developing treatments for...
FDA grants approval for two Eylea biosimilars for eye conditions
Pharmaceutical Technology via Yahoo Finance· 24 hours agoThe US Food and Drug Administration (FDA) has approved Yesafili (aflibercept-jbvf) and Opuviz...
US FDA staff says Guardant's test may fail to detect some pre-cancerous tumors
AOL· 19 hours agoThe reviewers, however, said the test may increase compliance with screening for colorectal cancer and help detect it in earlier stages, potentially helping cure patients and prolong survival ...
Larimar's Friedreich's ataxia program free at last from FDA hold
FierceBiotech· 18 hours agoLarimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a...
Biocon Biologics gets US FDA nod for biosimilar version of eye treatment drug Eylea
Investing.com· 1 day agoBiocon Biologics gets US FDA nod for biosimilar version of eye treatment drug Eylea
FDA Approves Boehringer Ingelheim’s CYLTEZO® Biosimilar to Humira for Multiple Chronic Inflammatory...
JD Supra· 1 day agoCYLTEZO was first approved in the US in 2017 and later approved in the US as an interchangeable biosimilar to Humira in October 2021. A lower concentration version of CYLTEZO (50 mg/mL) has been on the market since July 2023.